Understanding the pharmacokinetics of anxiolytic drugs

Author： Altamura Alfredo Carlo   Moliterno Donatella   Paletta Silvia   Maffini Michele   Mauri Massimo Carlo   Bareggi Silvio  

Publisher： Informa Healthcare

ISSN： 1742-5255

Source： Expert Opinion on Drug Metabolism and Toxicology, Vol.9, Iss.4, 2013-04, pp. : 423-440

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Potential Novel Anxiolytic Drugs

By  

Current Pharmaceutical Design, Vol. 14, Iss. 33, 2008-11 ,pp. : 3534-3546

Bentham Science Publishers

Access to resources Recommend Favorite

Clinical Pharmacokinetics and Pharmacodynamics of Buspirone, an Anxiolytic Drug

By Mahmood I.   Sahajwalla C.  

Clinical Pharmacokinetics, Vol. 36, Iss. 4, 1999-04 ,pp. : 277-287

Adis International

Access to resources Recommend Favorite

The GABAA-BZR Complex as Target for the Development of Anxiolytic Drugs

By  

Current Topics in Medicinal Chemistry, Vol. 12, Iss. 4, 2012-02 ,pp. : 254-269

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacogenetics and pharmacokinetics of HIV drugs

By Dingermann Theo   Zündorf Ilse  

PHARMAKON, Vol. 2, Iss. 5, 2014-09 ,pp. : 348-354

Govi-Verlag

Access to resources Recommend Favorite

Pharmacokinetics of Deramciclane, a Novel Anxiolytic Agent, after Intravenous and Oral Administration

By Huupponen R.   Paija O.  

Drugs in R&D, Vol. 4, Iss. 6, 2003-01 ,pp. : 339-345

Adis International

Access to resources Recommend Favorite